eFFECTOR Therapeutics

eFFECTOR Therapeutics EBITDA per Share

The EBITDA per Share of eFFECTOR Therapeutics (EFTR) as of Oct 18, 2026 is -15.48 USD. In the previous year, EBITDA per Share was -19.67 USD — a change of -21.34% (higher).

EBITDA per Share

-15.48USD

YoY

-21.34%

Last updated:

EBITDA per Share of eFFECTOR Therapeutics is 2023 -15.48 USD. EBITDA per Share of eFFECTOR Therapeutics was 2022 -19.67 USD. It decreases by -21.34% higher compared to the previous year.

The eFFECTOR Therapeutics EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2019
-17.58 USD
Jan 1, 2020
9.72 USD
Jan 1, 2021
-19.60 USD
Jan 1, 2022
-19.67 USD
Jan 1, 2023
-15.48 USD
The eFFECTOR Therapeutics EBITDA per Share history
YEAREBITDA per ShareYoY
-15.48USD-21.34%
-19.67USD+0.35%
-19.60USD-301.64%
9.72USD-155.30%
-17.58USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

eFFECTOR Therapeutics Stock analysis

What does eFFECTOR Therapeutics do? eFFECTOR Therapeutics Inc, based in Solana Beach, US, is a clinical-stage biopharmaceutical company specializing in oncology drug development. The company focuses on selective translation regulator inhibitors (STRIs), targeting the eIF4F complex and MNK kinase. Its lead candidate tomivosertib, in a Phase 2b trial with KEYTRUDA for metastatic NSCLC, and second candidate zotatifin, in Phase 1/2 trials for solid tumors, are part of its pipeline. The company, listed on January 8, 2021, employs 15 people. eFFECTOR Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about eFFECTOR Therapeutics stock

EBITDA per Share of eFFECTOR Therapeutics is -15.48 USD in 2023.

EBITDA per Share of eFFECTOR Therapeutics changed from -19.67 USD to -15.48 USD, representing a -21.34% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share eFFECTOR Therapeutics since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — eFFECTOR Therapeutics

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — eFFECTOR Therapeutics